Therefore, we initiated a real-world study to investigate the distribution and therapeutic responses in advanced NSCLC patients harboring uncommon EGFR alterations who were treated under four different treatment patterns: 1G EGFR-TKIs (gefitinib, erlotinib or icotinib), 2G EGFR-TKI afatinib, chemotherapy, and 1G EGFR-TKI in combination with chemotherapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.